专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5393513A Stable, highly concentrated fluoro carbon emulsions 失效
标题翻译：稳定，高度浓缩的氟碳乳液
公开(公告)号：US5393513A
公开(公告)日：1995-02-28
申请号：US100664
申请日：1993-07-30
申请人： David M. Long, Jr.
发明人： David M. Long, Jr.
IPC分类号： A61K9/00 , A61K31/02 , A61K49/04 , A61B5/055 , A61K31/35 , A61K31/56
CPC分类号： A61K9/0026 , A61K31/02 , Y10S514/832 , Y10S514/937 , Y10S514/941 , Y10S514/943 , Y10S977/904 , Y10S977/915 , Y10S977/927 , Y10T436/24
摘要： A non-toxic, brominated perfluorocarbon emulsion for internal and intravenous use in animals (including humans) is disclosed, for use as an oxygen transport medium and as a contrast enhancement medium capable of facilitating the detection of tumors and other elements within the body. This emulsion is stable and maintains its very small particle size characteristics for extended periods of time, often exceeding eighteen months after sterilization, and further may include a stabilizing component selected from the group consisting of steroids, tocopherols, cholesterols, and combinations thereof. An anti-oxidizing component enhances delivery in oxygen transport.
摘要翻译：公开了用于动物（包括人）内部和静脉内使用的无毒溴化全氟化碳乳液，用作氧传输介质和能够促进体内肿瘤和其它元件的检测的对比增强介质。该乳液是稳定的，并且在灭菌后通常超过十八个月，并且可以包括选自类固醇，生育酚，胆固醇及其组合的稳定组分，延长的时间段保持其非常小的粒度特征。抗氧化组分增强了氧运输中的输送。

2. 发明授权

US5391376A Method for preventing and treating cachexia 失效
标题翻译：预防和治疗恶病质的方法
公开(公告)号：US5391376A
公开(公告)日：1995-02-21
申请号：US122192
申请日：1993-09-15
申请人： David M. Long, Jr. , Raymond A. Long
发明人： David M. Long, Jr. , Raymond A. Long
IPC分类号： A61K9/107 , A61K9/127 , A61K9/16 , A61K9/50 , A61K31/44 , A61K31/455 , A61K47/48 , A61K49/00 , A61K49/04 , A61K49/18 , A61K31/33
CPC分类号： A61K31/70 , A61K31/44 , A61K31/455 , A61K47/48853 , A61K49/0433 , A61K49/0471 , A61K49/1806 , A61K49/1812 , A61K49/1821 , Y10S514/814 , Y10S514/832 , Y10S514/963
摘要： The present invention relates to method for preventing or treating cachexia in a mammal based on the administration of a therapeutically effective amount of an anti-cachexia agent. Suitable agents include ADP-ribose-polymerase inhibitors, ADP-ribose-transferase inhibitors, NADase inhibitors, nicotinamide benzamide, theophylline, thymine and analogs thereof.
摘要翻译：本发明涉及基于施用治疗有效量的抗恶病质剂来预防或治疗哺乳动物的恶病质的方法。合适的试剂包括ADP-核糖聚合酶抑制剂，ADP-核糖转移酶抑制剂，NADase抑制剂，烟酰胺苯甲酰胺，茶碱，胸腺嘧啶及其类似物。

3. 发明授权

US5264220A Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents 失效
标题翻译：延长微粒治疗和颗粒物诊断剂血管停留时间的方法
公开(公告)号：US5264220A
公开(公告)日：1993-11-23
申请号：US790855
申请日：1991-11-12
申请人： David M. Long, Jr. , Raymond A. Long
发明人： David M. Long, Jr. , Raymond A. Long
IPC分类号： A61K9/107 , A61K9/127 , A61K9/16 , A61K9/50 , A61K31/44 , A61K31/455 , A61K47/48 , A61K49/00 , A61K49/04 , A61K49/18 , A61K9/121
CPC分类号： A61K31/70 , A61K31/44 , A61K31/455 , A61K47/48853 , A61K49/0433 , A61K49/0471 , A61K49/1806 , A61K49/1812 , A61K49/1821 , Y10S514/814 , Y10S514/832 , Y10S514/963
摘要： The present invention relates to a composition for increasing the vascular dwell-time of a particulate therapeutic or diagnostic agent in a mammal through the adjunct administration of an effective amount of the particulate therapeutic or diagnostic agent and an effective amount of a vascular dwell-time enhancing agent. Suitable therapeutic and diagnostic agents include those whose efficacy within the body is predicated on their ability to remain within or to be carried within the vascular compartment. Accordingly this method can be readily adapted for treating several diseases and disorders, including hypoxia, hypoxemia, anemia and cancer and for imaging selected regions of a mammal by various imaging techniques, including ultrasound imaging, X-ray imaging and MRI imaging.
摘要翻译：本发明涉及一种用于通过辅助施用有效量的颗粒治疗或诊断剂和有效量的血管停留时间增强来增加哺乳动物中颗粒状治疗剂或诊断剂的血管停留时间的组合物代理商合适的治疗剂和诊断剂包括其在体内的功效取决于其保留在血管室内或在血管隔室内携带的能力的那些。因此，该方法可以容易地适用于治疗几种疾病和障碍，包括缺氧，低氧血症，贫血和癌症，并且通过各种成像技术（包括超声成像，X射线成像和MRI成像）对哺乳动物的选定区域进行成像。

4. 发明授权

US4987154A Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use 失效
标题翻译：生物相容，稳定和浓缩的氟碳乳液，用于内部动物使用中的对比增强和氧气输送
公开(公告)号：US4987154A
公开(公告)日：1991-01-22
申请号：US82846
申请日：1987-08-05
申请人： David M. Long, Jr.
发明人： David M. Long, Jr.
IPC分类号： A61K9/00 , A61K31/02
CPC分类号： A61K9/0026 , A61K31/02 , Y10S514/832 , Y10S977/738 , Y10S977/773 , Y10S977/895 , Y10S977/902 , Y10S977/906 , Y10S977/915
摘要： An up to 125% fluorocarbon emulsion for use in or with animal bodies and organs thereof, maintains emulsion stability through normal sterilization procedures with selective osmotic and buffering agents, maintains the emulsion at within predetermined osmolarity levels and, when desired, free of excessive calcium precipitation, reduces in vivo and in vitro red blood cell injury, reduces adverse anemia effects, reduces viscosity and reduces the rate of oxidation, and tends to equilibrate its distribution in major body organs thereby reducing toxicity. The osmotic agents may buffer and may provide nutrient in the form of sugars. The osmotic and buffering agents can comprise, selectively, hexahydric alcohols, namely mannitol and sorbitol; certain sugars, namely glucose, mannose and fructose; along with buffering agents that will affect osmolarity including imidazole, tris(hydroxymethyl)aminomethane, sodium chloride, sodium bicarbonate, monobasic potassium phosphate, dibasic potassium phosphate, calcium chloride, magnesium sulfate, monobasic sodium phosphate, dibasic sodium phosphate or combinations of them. The emulsion may include tocopherol. A method of emulsifying the fluorocarbon includes forced flow impingement under pressure after mixing the fluorocarbon into the discontinuous phase. The fluorocarbon emulsion can be used to deliver drugs and medicines soluble in, or transportable by the emulsion.
摘要翻译：用于动物体及其器官中的高达125％的氟碳乳液，通过选择渗透和缓冲剂的正常灭菌程序保持乳液稳定性，将乳液保持在预定的渗透压浓度范围内，并且当需要时，不含过量的钙沉淀减少体内和体外红细胞损伤，减少不良的贫血作用，降低粘度和降低氧化速率，并趋于平衡其在主体器官中的分布，从而降低毒性。渗透剂可以缓冲并且可以以糖的形式提供营养物质。渗透和缓冲剂可以选择性地包含六元醇，即甘露糖醇和山梨糖醇; 某些糖，即葡萄糖，甘露糖和果糖; 以及将影响渗透压的缓冲剂，包括咪唑，三（羟甲基）氨基甲烷，氯化钠，碳酸氢钠，一磷酸钾，磷酸氢二钾，氯化钙，硫酸镁，磷酸二氢钠，磷酸氢二钠或它们的组合。乳液可以包括生育酚。将碳氟化合物乳化的方法包括在将碳氟化合物混入不连续相之后的压力下的强制流动冲击。氟碳乳液可用于输送可溶于乳剂或可由乳剂运输的药物和药物。

5. 发明授权

US5679394A Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents 失效
标题翻译：延长微粒治疗和颗粒物诊断剂血管停留时间的方法
公开(公告)号：US5679394A
公开(公告)日：1997-10-21
申请号：US379249
申请日：1995-01-27
申请人： David M. Long, Jr. , Raymond A. Long
发明人： David M. Long, Jr. , Raymond A. Long
IPC分类号： A61K9/107 , A61K9/127 , A61K9/16 , A61K9/50 , A61K31/44 , A61K31/455 , A61K47/48 , A61K49/00 , A61K49/04 , A61K49/18
CPC分类号： A61K31/70 , A61K31/44 , A61K31/455 , A61K47/48853 , A61K49/0433 , A61K49/0471 , A61K49/1806 , A61K49/1812 , A61K49/1821 , Y10S514/814 , Y10S514/832 , Y10S514/963
摘要： The present invention relates to a composition for increasing the vascular dwell-time of a particulate therapeutic or diagnostic agent in a mammal through the adjunct administration of an effective amount of the particulate therapeutic or diagnostic agent and an effective amount of a vascular dwell-time enhancing agent. Suitable therapeutic and diagnostic agents include those whose efficacy within the body is predicated on their ability to remain within or to be carried within the vascular compartment. Accordingly this method can be readily adapted for treating several diseases and disorders, including hypoxia, hypoxemia, anemia and cancer and for imaging selected regions of a mammal by various imaging techniques, including ultrasound imaging, X-ray imaging and MRI imaging.
摘要翻译：本发明涉及一种用于通过辅助施用有效量的颗粒治疗或诊断剂和有效量的血管停留时间增强来增加哺乳动物中颗粒状治疗剂或诊断剂的血管停留时间的组合物代理商合适的治疗剂和诊断剂包括其在体内的功效取决于其保留在血管室内或在血管隔室内携带的能力的那些。因此，该方法可以容易地适用于治疗几种疾病和障碍，包括缺氧，低氧血症，贫血和癌症，并且通过各种成像技术（包括超声成像，X射线成像和MRI成像）对哺乳动物的选定区域进行成像。

6. 发明授权

US4073879A Brominated perfluorocarbon radiopaque agents 失效
标题翻译：溴化全氟化碳不透射线剂
公开(公告)号：US4073879A
公开(公告)日：1978-02-14
申请号：US714392
申请日：1976-08-16
申请人： David M. Long, Jr.
发明人： David M. Long, Jr.
IPC分类号： A61K49/04 , A61K29/02
CPC分类号： A61K49/0461
摘要： Brominated cyclic and dibrominated aliphatic perfluorocarbons are useful as radiopaque agents for examination of the body of an animal.
摘要翻译：溴化环状和二溴化脂肪族全氟化碳可用作检查动物身体的不透射线剂。

7. 发明授权

US5847009A Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions 失效
标题翻译：在氟碳乳液中肠胃外给药颗粒分散体的预防措施
公开(公告)号：US5847009A
公开(公告)日：1998-12-08
申请号：US138485
申请日：1993-10-15
申请人： David M. Long, Jr.
发明人： David M. Long, Jr.
IPC分类号： A61K9/00 , A61K31/02 , A61K31/19 , A61K31/405 , A61K31/415 , A61K31/44 , A61K31/57 , A61K31/60 , A61K47/18 , A61K49/04 , A61K31/03 , A61K31/58 , A61K33/14
CPC分类号： A61K9/0026 , A61K31/02 , A61K31/19 , A61K31/405 , A61K31/415 , A61K31/44 , A61K31/57 , A61K31/60 , A61K47/183 , A61K49/0471 , A61K9/0019 , Y10S514/937
摘要： Methods for preventing or ameliorating the transient adverse physiological response to particulate dispersions (TAPR response) when these dispersions are administered parenterally to a patient. The methods comprise the administration of a prophylactic anti-inflammatory drug prior to administration of the particulate-containing material, and optionally during administration as well. Preferred drugs are cyclooxygenase inhibitors and corticosteroids.
摘要翻译：当将这些分散体肠胃外给予患者时，用于预防或改善对颗粒分散体（TAPR反应）的暂时不良生理反应的方法。所述方法包括在施用含颗粒材料之前以及任选地在施用期间施用预防性抗炎药物。优选的药物是环加氧酶抑制剂和皮质类固醇。

8. 发明授权

US5080885A Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport 失效
标题翻译：溴化全氟化碳乳液，用于内部动物用于对比增强和氧气运输
公开(公告)号：US5080885A
公开(公告)日：1992-01-14
申请号：US387947
申请日：1989-08-24
申请人： David M. Long, Jr.
发明人： David M. Long, Jr.
IPC分类号： A61K9/00 , A61K31/02
CPC分类号： A61K9/0026 , A61K31/02 , Y10S514/832 , Y10S514/937 , Y10S514/941 , Y10S514/943 , Y10S977/904 , Y10S977/915 , Y10S977/927 , Y10T436/24
摘要： A non-toxic, brominated perfluorocarbon emulsion for internal and intravenous use in animals (including humans) is disclosed, for use as an oxygen transport medium and as a contrast enhancement medium capable of facilitating the detection of tumors and other elements within the body. This emulsion is stable and maintains its very small particle size characteristics for extended periods of time, often exceeding eighteen months after sterilization, and further may include a stabilizing component selected from the group consisting of steroids, tocopherols, cholesterols, and combinations thereof. An anti-oxidizing component enhances delivery in oxygen transport.
摘要翻译：公开了用于动物（包括人）内部和静脉内使用的无毒溴化全氟化碳乳液，用作氧传输介质和能够促进体内肿瘤和其它元件的检测的对比增强介质。该乳液是稳定的，并且在灭菌后通常超过十八个月，并且可以包括选自类固醇，生育酚，胆固醇及其组合的稳定组分，延长的时间段保持其非常小的粒度特征。抗氧化组分增强了氧运输中的输送。

9. 发明授权

US5697369A Method and apparatus for disease, injury and bodily condition screening or sensing 失效
标题翻译：用于疾病，损伤和身体状况筛选或感测的方法和装置
公开(公告)号：US5697369A
公开(公告)日：1997-12-16
申请号：US352504
申请日：1994-12-09
申请人： David M. Long, Jr. , Mark L. Faupel
发明人： David M. Long, Jr. , Mark L. Faupel
IPC分类号： A61B5/04 , A61B5/0408 , A61B5/05 , A61B5/053 , G06N3/04
CPC分类号： A61B5/4312 , A61B5/04 , A61B5/04002 , A61B5/04085 , A61B5/05 , A61B5/0531 , A61B5/7264 , G06N3/0454 , A61B2562/0209 , A61B2562/046 , A61B5/7267 , Y10S706/924
摘要： A method and apparatus for measuring biopotentials at a test site on a human or animal subject and determining therefrom the existence or status of a condition at such test site. The efficacy of treatment of a condition is monitored by comparing values obtained from biopotentials taken before treatment with those obtained during or after treatment. For disease diagnosis or screening, values obtained from biopotential measurements taken during a test period are processed in a neural network which has been programmed to recognize potential value patterns indicative of a disease condition.
摘要翻译：一种用于在人或动物受试者的测试部位测量生物电位的方法和装置，从而确定在该测试部位处的状况的存在或状态。通过比较从治疗前获得的生物电位获得的值与在治疗期间或之后获得的那些值来监测病症治疗的功效。对于疾病诊断或筛选，在测试期间获得的生物电位测量获得的值在神经网络中进行处理，神经网络已被编程以识别指示疾病状况的潜在值模式。

10. 发明授权

US5077036A Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid 失效
标题翻译：用于对比增强和氧传输的生物相容稳定的氟碳乳液，其包含与磷脂结合的40-125重量/体积的碳氟化合物
公开(公告)号：US5077036A
公开(公告)日：1991-12-31
申请号：US501594
申请日：1990-03-30
申请人： David M. Long, Jr.
发明人： David M. Long, Jr.
IPC分类号： A61K9/00 , A61K31/02
CPC分类号： A61K9/0026 , A61K31/02 , Y10S514/832 , Y10S514/887 , Y10S514/941 , Y10S514/943 , Y10S977/915 , Y10S977/927
摘要： Biocompatible fluorcarbon emulsions having fluorocarbon in concentrations of from 75% weight per volume to 125% weight per volume have small, biocompatible particle size stability through heat sterilization with one emulsifying agent, including phospholipids, in concentrations of from 3% to 7% weight per volume. The single emulsifying agent can be hydrogenated lecithins and synthesized lecithins. Fluorocarbon emulsions having fluorocarbon in concentrations of from 40% weight per volume to 125% weight per volume have stability of partial pressure of oxygen and of partial pressure of carbon dioxide through heat sterilization and storage for extended periods of time after having been oxygenated with dissolved oxygen.
摘要翻译：具有浓度为每体积75重量％至每个体积125重量％的碳氟化合物的生物相容性氟碳乳液通过用一种乳化剂（包括磷脂）通过加热灭菌具有小的生物相容性粒度稳定性，其浓度为3体积％至7体积％体积。单一乳化剂可以是氢化卵磷脂和合成卵磷脂。具有浓度为每体积40重量％至125重量％的碳氟化合物的碳氟化合物乳液通过在用溶解氧充氧后通过加热灭菌和储存更长时间的时间而具有氧分压和二氧化碳分压的稳定性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式